Investors bought shares of Allergan PLC (NYSE:AGN) on weakness during trading hours on Thursday. $324.28 million flowed into the stock on the tick-up and $231.47 million flowed out of the stock on the tick-down, for a money net flow of $92.81 million into the stock. Of all equities tracked, Allergan PLC had the 4th highest net in-flow for the day. Allergan PLC traded down ($4.68) for the day and closed at $255.56

Several brokerages have issued reports on AGN. Leerink Swann raised their price objective on shares of Allergan PLC from $272.00 to $294.00 and gave the stock an “outperform” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of Allergan PLC from a “buy” rating to a “hold” rating in a research report on Tuesday. Vetr upgraded shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 price objective for the company in a research report on Monday, July 25th. Credit Suisse Group AG began coverage on shares of Allergan PLC in a research report on Monday, July 25th. They set an “outperform” rating and a $327.00 price objective for the company. Finally, Mizuho restated a “hold” rating and set a $232.00 price objective on shares of Allergan PLC in a research report on Monday, July 11th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Allergan PLC has an average rating of “Buy” and a consensus target price of $308.74.

The company has a market cap of $100.06 billion and a PE ratio of 22.64. The firm has a 50 day moving average price of $239.70 and a 200-day moving average price of $253.84.

Allergan PLC (NYSE:AGN) last announced its quarterly earnings results on Tuesday, May 10th. The company reported $3.04 EPS for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.01. The business had revenue of $3.80 billion for the quarter, compared to analysts’ expectations of $3.97 billion. The business’s quarterly revenue was up 48.1% on a year-over-year basis. Equities analysts expect that Allergan PLC will post $14.17 EPS for the current year.

In other Allergan PLC news, CFO Maria Teresa Hilado purchased 661 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The shares were bought at an average cost of $241.57 per share, for a total transaction of $159,677.77. Following the purchase, the chief financial officer now owns 11,957 shares of the company’s stock, valued at approximately $2,888,452.49. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nesli Basgoz sold 459 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $225.10, for a total transaction of $103,320.90. Following the sale, the director now owns 5,242 shares in the company, valued at $1,179,974.20. The disclosure for this sale can be found here.

Several hedge funds have made changes to their positions in AGN. Eaton Vance Management boosted its stake in shares of Allergan PLC by 276.7% in the fourth quarter. Eaton Vance Management now owns 793,555 shares of the company’s stock worth $247,986,000 after buying an additional 582,890 shares during the last quarter. State of Tennessee Treasury Department boosted its stake in shares of Allergan PLC by 135.7% in the fourth quarter. State of Tennessee Treasury Department now owns 466,141 shares of the company’s stock worth $145,669,000 after buying an additional 268,357 shares during the last quarter. Cibc World Markets Corp acquired a new stake in shares of Allergan PLC during the fourth quarter worth approximately $48,916,000. Edgewood Management LLC boosted its stake in shares of Allergan PLC by 10.9% in the fourth quarter. Edgewood Management LLC now owns 1,459,579 shares of the company’s stock worth $456,118,000 after buying an additional 143,657 shares during the last quarter. Finally, Employees Retirement System of Texas boosted its stake in shares of Allergan PLC by 265.5% in the fourth quarter. Employees Retirement System of Texas now owns 148,258 shares of the company’s stock worth $46,331,000 after buying an additional 107,700 shares during the last quarter.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.